ACADIA Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference Transcript
Welcome.
Thank you.
For those who may not be as familiar with ACADIA Pharmaceuticals, can you provide a brief introduction?
Yeah, sure. So at ACADIA, we focus on areas of high unmet need where typically there are no drugs approved. So we have two commercial products, NUPLAZID for Parkinson's disease psychosis where we are in our eight year since launch and DAYBUE for Rett syndrome, where we're in our first full calendar year of launch this year.
Each of those franchises are cash flow positive, we're a very cash flow positive company as an entity and with a very strong balance sheet. And in addition to leveraging those two franchises, we have two late-stage programs, one in for Prader-Willi syndrome, another rare disease in addition to Rett syndrome. And then we have a Phase 2
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
